BRIDGEBIO PHARMA INC (1BBIO.MI) Fundamental Analysis & Valuation

BIT:1BBIO • US10806X1028

Current stock price

64.23 EUR
+5.07 (+8.57%)
Last:

This 1BBIO.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. 1BBIO.MI Profitability Analysis

1.1 Basic Checks

  • In the past year 1BBIO has reported negative net income.
  • 1BBIO had a negative operating cash flow in the past year.
  • In the past 5 years 1BBIO always reported negative net income.
  • 1BBIO had a negative operating cash flow in each of the past 5 years.
1BBIO.MI Yearly Net Income VS EBIT VS OCF VS FCF1BBIO.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200M -400M -600M

1.2 Ratios

  • 1BBIO has a worse Return On Assets (-77.45%) than 77.78% of its industry peers.
Industry RankSector Rank
ROA -77.45%
ROE N/A
ROIC N/A
ROA(3y)-84.48%
ROA(5y)-77.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1BBIO.MI Yearly ROA, ROE, ROIC1BBIO.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

1.3 Margins

  • 1BBIO has a Gross Margin of 95.82%. This is amongst the best in the industry. 1BBIO outperforms 88.89% of its industry peers.
  • 1BBIO's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for 1BBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.85%
1BBIO.MI Yearly Profit, Operating, Gross Margins1BBIO.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. 1BBIO.MI Health Analysis

2.1 Basic Checks

  • 1BBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • 1BBIO has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for 1BBIO has been increased compared to 5 years ago.
  • The debt/assets ratio for 1BBIO is higher compared to a year ago.
1BBIO.MI Yearly Shares Outstanding1BBIO.MI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
1BBIO.MI Yearly Total Debt VS Total Assets1BBIO.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • Based on the Altman-Z score of -3.40, we must say that 1BBIO is in the distress zone and has some risk of bankruptcy.
  • 1BBIO's Altman-Z score of -3.40 is on the low side compared to the rest of the industry. 1BBIO is outperformed by 75.31% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.4
ROIC/WACCN/A
WACC8.84%
1BBIO.MI Yearly LT Debt VS Equity VS FCF1BBIO.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B -1B 2B -2B

2.3 Liquidity

  • A Current Ratio of 2.77 indicates that 1BBIO has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.77, 1BBIO perfoms like the industry average, outperforming 54.32% of the companies in the same industry.
  • 1BBIO has a Quick Ratio of 2.68. This indicates that 1BBIO is financially healthy and has no problem in meeting its short term obligations.
  • 1BBIO has a Quick ratio (2.68) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.77
Quick Ratio 2.68
1BBIO.MI Yearly Current Assets VS Current Liabilites1BBIO.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. 1BBIO.MI Growth Analysis

3.1 Past

  • The earnings per share for 1BBIO have decreased strongly by -22.33% in the last year.
  • The Revenue has grown by 126.26% in the past year. This is a very strong growth!
  • The Revenue has been growing by 127.44% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-22.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)126.26%
Revenue growth 3Y86.3%
Revenue growth 5Y127.44%
Sales Q2Q%2521.18%

3.2 Future

  • The Earnings Per Share is expected to grow by 36.10% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, 1BBIO will show a very strong growth in Revenue. The Revenue will grow by 52.14% on average per year.
EPS Next Y46.69%
EPS Next 2Y47.02%
EPS Next 3Y43.79%
EPS Next 5Y36.1%
Revenue Next Year87.45%
Revenue Next 2Y80.48%
Revenue Next 3Y69.38%
Revenue Next 5Y52.14%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
1BBIO.MI Yearly Revenue VS Estimates1BBIO.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B 4B 5B
1BBIO.MI Yearly EPS VS Estimates1BBIO.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. 1BBIO.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 1BBIO. In the last year negative earnings were reported.
  • Also next year 1BBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
1BBIO.MI Price Earnings VS Forward Price Earnings1BBIO.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1BBIO.MI Per share data1BBIO.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

  • 1BBIO's earnings are expected to grow with 43.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.02%
EPS Next 3Y43.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 1BBIO.MI Dividend Analysis

5.1 Amount

  • No dividends for 1BBIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

1BBIO.MI Fundamentals: All Metrics, Ratios and Statistics

BRIDGEBIO PHARMA INC

BIT:1BBIO (4/13/2026, 7:00:00 PM)

64.23

+5.07 (+8.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.66
Industry Growth13.04
Earnings (Last)02-24
Earnings (Next)04-30
Inst Owners93.02%
Inst Owner ChangeN/A
Ins Owners4.08%
Ins Owner ChangeN/A
Market Cap12.45B
Revenue(TTM)502.08M
Net Income(TTM)-724.93M
Analysts85.52
Price Target84.5 (31.56%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.46%
Min EPS beat(2)-32.11%
Max EPS beat(2)-4.81%
EPS beat(4)1
Avg EPS beat(4)-10.2%
Min EPS beat(4)-32.11%
Max EPS beat(4)6.56%
EPS beat(8)3
Avg EPS beat(8)8.26%
EPS beat(12)3
Avg EPS beat(12)0.75%
EPS beat(16)5
Avg EPS beat(16)5.97%
Revenue beat(2)2
Avg Revenue beat(2)7.09%
Min Revenue beat(2)2.94%
Max Revenue beat(2)11.23%
Revenue beat(4)4
Avg Revenue beat(4)29.34%
Min Revenue beat(4)2.94%
Max Revenue beat(4)84.61%
Revenue beat(8)6
Avg Revenue beat(8)186.1%
Revenue beat(12)6
Avg Revenue beat(12)110.2%
Revenue beat(16)7
Avg Revenue beat(16)90.78%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0.54%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-6.96%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-1.03%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.69%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.05
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.23
EYN/A
EPS(NY)-1.72
Fwd EYN/A
FCF(TTM)-2.01
FCFYN/A
OCF(TTM)-1.96
OCFYN/A
SpS2.21
BVpS-9.19
TBVpS-9.31
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -77.45%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.82%
FCFM N/A
ROA(3y)-84.48%
ROA(5y)-77.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.85%
F-Score3
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 176.52%
Cap/Sales 1.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.77
Quick Ratio 2.68
Altman-Z -3.4
F-Score3
WACC8.84%
ROIC/WACCN/A
Cap/Depr(3y)114.42%
Cap/Depr(5y)132.7%
Cap/Sales(3y)6.65%
Cap/Sales(5y)9.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y46.69%
EPS Next 2Y47.02%
EPS Next 3Y43.79%
EPS Next 5Y36.1%
Revenue 1Y (TTM)126.26%
Revenue growth 3Y86.3%
Revenue growth 5Y127.44%
Sales Q2Q%2521.18%
Revenue Next Year87.45%
Revenue Next 2Y80.48%
Revenue Next 3Y69.38%
Revenue Next 5Y52.14%
EBIT growth 1Y13.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.7%
EBIT Next 3Y49.98%
EBIT Next 5Y33.32%
FCF growth 1Y14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.37%
OCF growth 3YN/A
OCF growth 5YN/A

BRIDGEBIO PHARMA INC / 1BBIO.MI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BRIDGEBIO PHARMA INC?

ChartMill assigns a fundamental rating of 3 / 10 to 1BBIO.MI.


What is the valuation status for 1BBIO stock?

ChartMill assigns a valuation rating of 1 / 10 to BRIDGEBIO PHARMA INC (1BBIO.MI). This can be considered as Overvalued.


How profitable is BRIDGEBIO PHARMA INC (1BBIO.MI) stock?

BRIDGEBIO PHARMA INC (1BBIO.MI) has a profitability rating of 1 / 10.